{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:14:59Z","timestamp":1761855299660,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nursing Clinics of North America"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.cnur.2018.07.004","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T14:15:09Z","timestamp":1537884909000},"page":"531-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Roles of Systemic Lupus Erythematosus and Immunoglobulin A Nephropathy in\u00a0Glomerular Disease"],"prefix":"10.1016","volume":"53","author":[{"given":"Stacey G.","family":"Browning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cnur.2018.07.004_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/ijmr.IJMR_1356_15","article-title":"Clinical and immunological characteristics in systemic lupus erythematosus patients","volume":"146","author":"Rastin","year":"2017","journal-title":"Indian J Med Res"},{"issue":"11","key":"10.1016\/j.cnur.2018.07.004_bib2","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.cnur.2018.07.004_bib3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/rheumatology\/kex332","article-title":"Systematic and local granzyme B levels are associated with disease activity, kidney damage and interferon signature in systemic lupus erythematosus","volume":"56","author":"Kok","year":"2017","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.cnur.2018.07.004_bib4","first-page":"17","article-title":"A\u00a0systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis","volume":"32","author":"Hong","year":"2017","journal-title":"Arch Rheumatol"},{"issue":"3","key":"10.1016\/j.cnur.2018.07.004_bib5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.ajkd.2016.12.008","article-title":"Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials","volume":"70","author":"Palmer","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.cnur.2018.07.004_bib6","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/acr.23161","article-title":"Disease outcomes and care fragmentation among patients with systemic lupus erythematosus","volume":"69","author":"Walunas","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.cnur.2018.07.004_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0961203317717082","article-title":"Disease-specific quality of life in patients with lupus nephritis","volume":"27","author":"Jolly","year":"2017","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.cnur.2018.07.004_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"51","key":"10.1016\/j.cnur.2018.07.004_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000009408","article-title":"Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis","volume":"96","author":"Tian","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.cnur.2018.07.004_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/7407919","article-title":"Immunosuppressive treatment for lupus nephritis: long-term results in 178 patients","volume":"2016","author":"Zakharova","year":"2016","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.cnur.2018.07.004_bib11","first-page":"521","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cnur.2018.07.004_bib12","unstructured":"Treating lupus with anti-malarial drugs. hopkinslupus.org. 2018. Available at: https:\/\/www.hopkinslupus.org\/lupus-treatment\/lupus-medications\/antimalarial-drugs\/. Accessed January 4, 2018."},{"key":"10.1016\/j.cnur.2018.07.004_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/ITT.S40675","article-title":"Current and emerging treatment options in the management of lupus","volume":"5","author":"Jordan","year":"2016","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.cnur.2018.07.004_bib14","unstructured":"Lupus detailed fact sheet. cdc.gov. 2018. Available at: https:\/\/www.cdc.gov\/lupus\/facts\/detailed.html. Accessed January 20, 2018."},{"issue":"3","key":"10.1016\/j.cnur.2018.07.004_bib15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.38983","article-title":"Sociodemographic and geographic predictors of quality of care in United States patients with end-stage renal disease due to lupus nephritis","volume":"67","author":"Plantinga","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.cnur.2018.07.004_bib16","first-page":"70","article-title":"The Outcome of patients with lupus nephritis and the impact of cardiovascular risk factors","volume":"37","author":"Drakoulogkona","year":"2011","journal-title":"Curr Health Sci J"},{"key":"10.1016\/j.cnur.2018.07.004_bib17","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1681\/ASN.2016040415","article-title":"Current and emerging therapies for lupus nephritis","volume":"27","author":"Parikh","year":"2016","journal-title":"J\u00a0Am Soc Nephol"},{"key":"10.1016\/j.cnur.2018.07.004_bib18","unstructured":"IgA Nephropathy (Berger\u2019s Disease). mayoclinic.org. 2015. Available at: https:\/\/www.mayoclinic.org\/diseases-conditions\/iga-nephropathy\/symptoms-causes\/syc-20352268. Accessed January 20, 2018."},{"key":"10.1016\/j.cnur.2018.07.004_bib19","first-page":"5","article-title":"Role of IgA receptors in the pathogenesis of IgA nephropathy","volume":"29","author":"Lechner","year":"2016","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.cnur.2018.07.004_bib20","unstructured":"IgA Nephropathy. kidney.org. 2017. Available at: https:\/\/www.kidney.org\/atoz\/content\/iganeph. Accessed January 20, 2018."},{"key":"10.1016\/j.cnur.2018.07.004_bib21","first-page":"551","article-title":"Treatment of IgA nephropathy with renal insufficiency","volume":"29","author":"Pozzi","year":"2016","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.cnur.2018.07.004_bib22","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.cnur.2018.07.004_bib23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/ki.2013.375","article-title":"Histologic classification of glomerular disease: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification","volume":"85","author":"Haas","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.cnur.2018.07.004_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10157-015-1195-y","article-title":"The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy","volume":"20","author":"Tanaka","year":"2016","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"10.1016\/j.cnur.2018.07.004_bib25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the testing randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cnur.2018.07.004_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.cnur.2018.07.004_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000422389","article-title":"Typical and atypical natural history of IgA nephropathy in adult patients","volume":"104","author":"D\u2019Amico","year":"1993","journal-title":"Contrib Nephrol"},{"issue":"6","key":"10.1016\/j.cnur.2018.07.004_bib28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2215\/CJN.02300215","article-title":"Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy","volume":"11","author":"Sarcina","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9156","key":"10.1016\/j.cnur.2018.07.004_bib29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cnur.2018.07.004_bib30","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"Pozzi","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cnur.2018.07.004_bib31","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.2215\/CJN.01170211","article-title":"The use of the oxford classification of IgA nephropathy to predict renal survival","volume":"6","author":"Alamartine","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"164","key":"10.1016\/j.cnur.2018.07.004_bib32","first-page":"1","article-title":"Vitamin D deficiency may predict a poorer outcome of IgA nephropathy","volume":"17","author":"Li","year":"2016","journal-title":"BMC Nephrol"},{"year":"2017","series-title":"Fundamentals of nursing","author":"Potter","key":"10.1016\/j.cnur.2018.07.004_bib33"}],"container-title":["Nursing Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0029646518300604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0029646518300604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T09:27:39Z","timestamp":1758446859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0029646518300604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0029646518300604"],"URL":"https:\/\/doi.org\/10.1016\/j.cnur.2018.07.004","relation":{},"ISSN":["0029-6465"],"issn-type":[{"type":"print","value":"0029-6465"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Roles of Systemic Lupus Erythematosus and Immunoglobulin A Nephropathy in\u00a0Glomerular Disease","name":"articletitle","label":"Article Title"},{"value":"Nursing Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cnur.2018.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}